Apraglutide

•  Treatment with apraglutide resulted in an average 50% reduction in Parenteral Support (PS) volume at six months •  80% of patients were clinical responders (defined as a reduction in…

-- Apraglutide, a next-generation GLP-2 analog, protected against chemotherapy-induced gastrointestinal (GI) damage and improved survival in mouse models of GI acute graft-versus-host…